News Search Results
Aug 06, 2024, 17:30 ET Luxury Eyewear Market size is set to grow by USD 3.94 billion from 2024-2028, Innovation and portfolio extension leading to product premiumization boost the market, Technavio
high-end, designer frames for sunglasses and eyeglasses. International institutions and trade associations, such as the International Council of Ophthalmology and the European Union Eyewear Industry Association, provide market insights and research. Market indicators, including fashion consciousness, radiation
More news about: Technavio
Aug 06, 2024, 14:55 ET Hospital Furniture Market size is set to grow by USD 8 billion from 2024-2028, Rise in international accreditation by hospitals boost the market, Technavio
Beds, Fowler Beds, Ordinary Hospital Beds, Pediatric Beds, Maternity Beds, and more. The Chairs sector includes Birthing Chairs, Dialysis Chairs, Ophthalmology Chairs, ENT Chairs, Dentistry Chairs, Pediatric Chairs, Bariatric Chairs, and Geriatric Chairs. End users include Hospitals, Diagnostic Centers,
More news about: Technavio
Aug 06, 2024, 08:30 ET InMode to Present at Upcoming Investor Conferences
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
More news about: InMode LTD
Aug 06, 2024, 08:00 ET Luminopia Covered by Highmark Health for Treatment of Pediatric Amblyopia
Ophthalmology,
More news about: Luminopia
Aug 06, 2024, 06:45 ET Mallinckrodt plc Reports Second Quarter 2024 Financial Results and Raises Full Year Guidance
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc
Aug 06, 2024, 06:35 ET Mallinckrodt Announces Availability of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector in the U.S.
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc
Aug 06, 2024, 04:57 ET Regenerative Medicine Market to Reach $531.7 Billion, Globally, by 2033 at 32.4% CAGR: Allied Market Research
Material, Genetically Engineered Material and Pharmaceutical), and Application (Cardiovascular, Oncology, Dermatology, Musculoskeletal, Wound Healing, Ophthalmology, Neurology and Others): Global Opportunity Analysis and Industry Forecast, 2024-2033". According to the report, the regenerative medicine market
More news about: Allied Market Research
Aug 05, 2024, 10:15 ET SKYE Investors Have Opportunity to Join Skye Bioscience, Inc. Fraud Investigation with the Schall Law Firm
("IOP"). Skye intends to discontinue clinical development and spending related to SBI-100 OE and any R&D associated with SBI-100, including its ophthalmology pipeline, and direct all clinical development resources to its metabolic program, extending its operating runway into 2027." Based on this news,
More news about: The Schall Law Firm
Aug 05, 2024, 07:57 ET Orbis International Brings the Flying Eye Hospital to Mongolia to Train Local Eye Care Teams
retinopathy of prematurity. Orbis Mongolia also trains critically needed eye health professionals in refraction (assessment for glasses) and pediatric ophthalmology, expands access to quality eye care services, provides essential equipment to partners, and works with policymakers to address unmet needs.
More news about: Orbis International
Aug 05, 2024, 07:00 ET Hyaluronic Acid Raw Material Market is projected to grow at a CAGR of 5.2%, Reaching a value of $11.7 billion by 2034 | Fact.MR Report
analyzed to reach US$ 11.7 billion by 2034.Worldwide demand for hyaluronic acid raw materials for use in ophthalmology is forecasted to increase at a CAGR of 5.7% and reach a market worth of US$ 2.68 billion by the end of 2034.Sales
More news about: Fact.MR
Aug 05, 2024, 07:00 ET Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc
Aug 05, 2024, 04:30 ET Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Ocular Surgery Relief and Recovery
with its storied history and reputation for success," said Erick Co, President and CEO of Formosa Pharmaceuticals. "Their commitment to branded ophthalmology products gives us full confidence that APP13007 will flourish in the Canadian market. We look forward to working with the Apotex team in providing
More news about: Formosa Pharmaceuticals Inc.,
Aug 03, 2024, 02:02 ET INAUGURAL NUHS SCIENTIFIC & INNOVATION SUMMIT CHAMPIONS PREDICTIVE, PRECISE AND PERSONALISED CARE
understand what we can do to improve the chances of curing more people." For A/Prof Su Xinyi, who is a senior consultant with the Department of Ophthalmology at NUH, precision medicine may be the key to restoring the vision of patients suffering from currently untreatable and blinding retinal diseases.
More news about: National University Health System (NUHS)
Aug 02, 2024, 11:45 ET Tidewater Clinical Research Acquired by Eximia Research Network
Since its founding in 1994, Tidewater Clinical Research has led advancements in Women's Health and Ophthalmology through clinical trials in the Hampton Roads/Eastern Virginia region. This integration
More news about: Viking Mergers & Acquisitions
Aug 01, 2024, 20:34 ET Innovent and SanegeneBio Announce First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA)
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, and Sanegene Bio USA Inc. (SanegeneBio) today announced the first participant has been
More news about: Innovent Biologics
Aug 01, 2024, 18:55 ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
("IOP"). Skye intends to discontinue clinical development and spending related to SBI-100 OE and any R&D associated with SBI-100, including its ophthalmology pipeline, and direct all clinical development resources to its metabolic program, extending its operating runway into 2027." On this news,
More news about: Pomerantz LLP
Aug 01, 2024, 10:30 ET Regenerative Medicine Market is estimated to register a CAGR of 27.2% by 2031, attributed to rise in investments in R&D to innovate product launches | SkyQuest Technology
EngineeringTherapeutic AreaOncology, Musculoskeletal Disorders, Dermatology & Wound Care, Cardiovascular Diseases, Ophthalmology, Neurology, and OthersRequest Free Customization of this report:
More news about: SkyQuest Technology
Aug 01, 2024, 08:59 ET Mallinckrodt to Report Earnings Results for Second Quarter 2024
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc
Aug 01, 2024, 07:00 ET InMode Reports Second Quarter 2024 Financial Results; Quarterly Revenue of $86.4M Represents 36.5% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet delivered) of $102.6M
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com. Forward-Looking
More news about: InMode LTD
Aug 01, 2024, 04:40 ET Innovent Announces the NDA of Mazdutide for Type 2 Diabetes has been Accepted by the NMPA of China
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the second New Drug Application (NDA) of mazdutide, a glucagon-like peptide-1 receptor (GLP-1R) and glucagon
More news about: Innovent Biologics
Jul 31, 2024, 17:15 ET Aesthetic Lasers And Energy Devices Market size is set to grow by USD 2.37 billion from 2024-2028, Increasing global awareness about medical aesthetics boost the market, Technavio
multi-specialty, standalone centers, and cosmetic surgery centers. Key applications include hair removal, skin rejuvenation, skin tightening, aesthetic ophthalmology, and body contouring. Technologies like laser resurfacing devices, body contouring devices, radiofrequency, and handheld devices cater to these
More news about: Technavio
Jul 31, 2024, 14:30 ET Diagnostic Imaging Market size is set to grow by USD 8.69 billion from 2023-2027, Increasing prevalence of chronic conditions to boost the market growth, Technavio
Deepmind and Moorfields Eye Hospital. The development of an optical CT scanner for age-related macular degeneration is a significant breakthrough in ophthalmology. The economic setback caused by the pandemic has led to an increase in demand for teleradiology services and refurbished equipment in developing
More news about: Technavio
Jul 31, 2024, 08:15 ET Eximia Research Network Expands into Virginia with Integration of Tidewater Clinical Research
clinical trial sites. This strategic development unites Tidewater's longstanding expertise in Women's Health and Ophthalmology with Eximia's extensive clinical trial experience and resources. Since its inception in 1994, Tidewater has led
More news about: Eximia Research
Jul 31, 2024, 08:03 ET InMode Introduces IgniteRF The Complete Minimally Invasive Soft Tissue Contraction Platform
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
More news about: InMode LTD
Jul 30, 2024, 21:59 ET ViaLase reçoit le marquage CE pour le premier laser Femtoseconde destiné au traitement du glaucome, le laser ViaLase®
YC, Xiang L, et al. Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040 : Une revue systématique et une méta-analyse. Ophthalmology 2014 ; 121(11) : 2081-2090.
More news about: ViaLase, Inc.